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Independent indices (height, body mass index, a body shape index, and hip index) derived from basic anthropometrics have been
found to be powerful predictors of mortality hazard, especially when the attributable risks are summed over these indices to give an
anthropometric risk index (ARI).+emetabolic syndrome (MS) is defined based on the co-occurrence of anthropometric, clinical, and
laboratory criteria and is also widely employed for evaluating disease risk. Here, we investigate correlations between ARI and MS in
a general population sample, the United States +ird National Health and Nutrition Examination Survey. Baseline values of ARI and
MS were also evaluated for their association with mortality over approximately 20 years of follow-up. ARI was found to be positively
correlated with each component of MS, suggesting connections between the two entities as measures of cardiometabolic risk. ARI and
MS were both significant predictors of mortality hazard. Although the association of ARI withmortality hazard was stronger than that
of MS, a combined model with both ARI andMS score as predictors improved predictive ability over either construct in isolation. We
conclude that the combination of anthropometrics and clinical and laboratory measurements holds the potential to increase the
effectiveness of risk assessment compared to using either anthropometrics or the current components of MS alone.
1. Introduction
In 2009, an international task force recognized metabolic
syndrome (MS) as a critical component in addressing car-
diovascular and mortality risk around the globe [1]. +e
diagnosis of MS is based on co-occurrence of hypertension (a
biophysical clinical measurement); elevated triglycerides, low
high-density cholesterol (HDL), and hyperglycemia (labo-
ratory measures); and elevated waist circumference (WC, an
anthropometric measurement). +ough there are differences
in detail between definitions of MS, above-threshold values of
each component are typically scored as one point, with a total
score of 3 or above indicative of MS. +e construct of MS has
succeeded in raising awareness among professionals and the
public of cardiometabolic risk at the individual and pop-
ulation levels and focusing attention on correcting abdominal
obesity and insulin resistance and continues to be the focus of
extensive research.
WC is the anthropometric component of the MS defi-
nition, and some authors even consider above-cutpoint WC
values to be mandatory for diagnosis of MS. WC concep-
tually is considered a measure of abdominal obesity, but
statistically it differs little from the even more widely used
body mass index (BMI), as the correlation between the two
in large population studies is typically close to 0.9. Given this
high correlation, BMI has even been taken to replaceWC for
the definition of MS in cohorts where WC data were un-
available [2]. A derivative of WC and hip circumference
(HC) that is also taken to indicate abdominal obesity is
WC/HC ratio [3–6], which has lesser, but still substantial
correlation with BMI of ∼0.4 [7].
A line of research that responds to these concerns about
the independence of anthropometric criteria has defined
a body shape index (ABSI), based on a power-law expression
that relates WC to height and weight (or equivalently height
and BMI) [8]. Height (H), BMI, and ABSI then are com-
plementary and independent indices that express the in-
formation provided by the basic measures of weight, height,
and WC. Similarly, a hip index (HI) was defined that
normalizes HC for BMI [7].
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ABSI and HI, unlike BMI, show strong sex and age
dependence. Accordingly, the risk attributable to ABSI and
HI is best expressed after transforming the raw values, for
example to Z scores adjusted for age and sex [7, 9]. Taking
advantage of the approximate statistical independence of the
indices H, BMI, ABSI, and HI, an anthropometric risk in-
dicator (ARI) was introduced, which combines hazard ratios
attributable to Z scores of the multiple independent indices
and results in improved discrimination of mortality risk
compared to using any one index in isolation [7, 10].
MS is known to be a risk factor for all-cause mortality, as
well as onset of cardiovascular disease and diabetes [11],
although whether it improves prediction over just using
some of its individual components continues to be in-
vestigated [2, 12, 13]. Similarly, the anthropometric indices
combined into ARI, particularly ABSI, have been shown to
predict mortality hazard and morbidity onset [14–25].
BMI and ABSI have been shown to correlate with the
components of MS [26–35]. However, there is limited in-
formation on how anthropometric risk (as measured by ARI)
overlaps with metabolic risk (as measured by MS score) in
populations.
In this study, we aim to answer two major questions.
First, how do anthropometric indices based on H, W, WC,
and HC correlate with MS in a general population sample?
Second, how do anthropometry-based risk and MS com-
plement each other as predictors of mortality hazard?
2. Methods
2.1. Data. +e +ird National Health and Nutrition Ex-
amination Survey (NHANES III) sampled the civilian
noninstitutionalized USA population during 1988–1994
using a cluster approach, with some groups of public health
interest (children, the elderly, black and Mexican-American
people) deliberately oversampled [36]. Mortality outcomes
for adult subjects were available from the National Center
for Health Statistics with follow-up through 2011 (17–23
years of follow-up). We analyzed NHANES III public-use
data for all nonpregnant adults (age 18 and over) with the
required measurements and mortality follow-up. About half
of the NHANES III cohort were examined in the morning,
and hence have the fasting triglyceride and glucose mea-
surements that are used to define MS.
2.2. ARI andMS. Anthropometric indices were calculated as
follows [7, 8, 37]:
BMI ≡W · H−2,
ABSI ≡WC · H5/6 · W−2/3,
HI ≡ HC · H
ÆHæ
( )
0.310
·
W
ÆWæ
( )
−0.482
,
(1)
where ÆHæ � 166 cm and ÆWæ � 73 kg are average values in-
cluded in the definition as scaling factors.
+e anthropometric index values for the NHANES III
cohort are converted to Z scores by subtracting the age and
sex specific mean and dividing by the standard deviation [7].
Penalized spline Cox proportional hazard regressions on the
subset of NHANES III that did not have the data needed to
determine MS score was used to estimate the natural loga-
rithm of the mortality hazard as a function of each anthro-
pometric index taken alone. +en, these estimated log hazard
ratios (resp. designated here hH, hBMI, hABSI, and hHI) are
computed for the Z score values of each subject in NHANES
III and summed to give ARI. +e estimated mortality hazard
for each combination of anthropometric indices, as a fraction
of the population mean hazard, is exp(ARI), so that ARI of
0 connotes population-average risk, while positive ARI
connotes above-average risk and negative ARI below-average
risk [7]. An online calculator that converts anthropometrics to
Z scores and gives ARI and its components is available at
https://www.nirkrakauer.net/sw/ari-calculator.html.
As previously done for NHANES III [38, 39], MS was
defined following the +ird Report of the National Choles-
terol Education Program Adult Treatment Panel (ATP III)
[40]. +is relies on the presence or absence (scored 1/0) of
each of five components: abdominal obesity (defined using
WC), hypertension, hypertriglyceridemia, low high-density
lipoprotein (HDL) levels, and hyperglycemia. +e exact cri-
teria used are given in Table 1. +e summed score can range
between 0 and 5, with a score of 3 or above constituting MS.
2.3. Prediction Models and Analysis. +e considered mor-
tality predictors in Cox proportional hazard modeling were
the anthropometric index (H, BMI, ABSI, and HI) hazard
ratio natural logarithms and their sum, the ARI; and the MS
components (coded 0-1), MS score (0–5), and MS occur-
rence (0-1). +e resulting predictive models considered are
listed and explained in Table 2. In line with previous analyses
of NHANES III [7], each prediction model also includes
black race (coded 0-1) and sex. Age was implicitly included,
being the timescale in the Cox model [8]. We used the
provided sample weights for the morning subsample [36] so
that our results would be better estimates for associations
with mortality hazard in the general USA population.
As in [7], the main measure of relative predictive perfor-
mance was AIC difference score, Δi. For the best-performing
Table 1: Metabolic syndrome components.
Component Criteria
Waist Waist circumference above 102 cm for men or 88 cmfor women.
BP
Systolic blood pressure at or above 130mmHg or
diastolic blood pressure at or above 85mmHg or
self-reported to be using blood pressure
medications.
TG Fasting serum triglycerides at or above 150mg/dL.
HDL Serum high-density lipoprotein cholesterol under40mg/dL for men, 50mg/dL for women.
Glu Fasting plasma glucose level at or above 110mg/dLor self-reported to be taking pills for diabetes.
Abbreviations for and definitions of metabolic syndrome components used
in this study. Each component is scored 1 if the criteria for it are met and
0 otherwise. A total score of 3 or above defines metabolic syndrome.
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model (with lowest AIC) Δi � 0, while other models have
positive Δi [41]. Δi > 6 indicated models that perform signifi-
cantly worse than the best-performing model (at the 95%
confidence level) as mortality predictors for the sampled
population [17].We also calculated coefficientsR2, denoting the
proportion of variation in mortality explained by the predictors
of each model, so that higher R2 suggests a model with greater
explanatory power [42]. Another measure of model perfor-
mance considered was concordance (C), defined as the fraction
of pairs of individuals in the sample for which the one modeled
to be at greater risk actually died sooner [43]. Concordance
ranges from 0 to 1, with 0.5 the expected value for models with
no skill and higher values indicating models that are more
skillful at explaining variation in survival. To better understand
the relationship between ARI, MS, and their components in the
NHANES III population, we also show and discuss the cor-
relation coefficients between them.
3. Results
+ere were 5221 nonpregnant adults in NHANES III who had
recorded all the measurements needed to evaluate the
anthropometric indices andMS components, out of whom1564
(30%) died during follow-up. Based on the definition used, 1449
people had MS at baseline, for an MS prevalence of 28%. Mean
ARI was near zero (−0.01), with a standard deviation of 0.23.
Correlation coefficients between the ARI-component
hazard ratios based on H, BMI, ABSI, and HI are consis-
tently very low in magnitude (under 0.1), which suggests that
the anthropometric indices chosen do measure statistically
independent components of mortality risk (Table 3). ARI is
the sum of these components, and their respective correla-
tions with ARI show that BMI is the largest contributor to
anthropometric mortality risk in NHANES III, followed by
ABSI and then HI, with H having negligible value for pre-
dicting mortality. +e MS components, in turn, are inter-
correlated, with correlation coefficients typically around 0.2,
consistent with their being parts of a larger syndrome that
nevertheless each add independent information (Table 3).
+ey each have correlations of 0.5–0.7 with their sum, the MS
score, and 0.4–0.6 with MS occurrence, with TG being the
best-correlated single component (Table 3).
ARI correlates positively with each of the MS compo-
nents, with the best correlation being with Waist. In fact,
Table 2: Predictive models considered.
Model Description
Base No anthropometric or MS predictors.
ARI ARI as a predictor.
MS MS occurrence as a predictor.
MS score MS score as a predictor.
ARI+MS ARI and MS occurrence as predictors.
ARI+MS score ARI and MS score as predictors.
ARI+MSx score
ARI and MS score (excluding Waist) as predictors. Excluding the WC component from the MS
score was hypothesized to be reasonable when considering it alongside ARI since the BMI and
ABSI components of ARI already correlate strongly with WC.
MS components +e 5 MS components as individual predictors. +is tested the relative utility of the componentsof MS, which could suggest refinements of its definition for testing in future work.
ARI+MS components ARI and the 5 MS components (Table 1) as individual predictors.
ARI+MSx components ARI and the 4 MS components (excluding Waist) as individual predictors.
Models for predicting mortality that were compared in this study. MS: metabolic syndrome; ARI: anthropometric risk index; WC: waist circumference; BMI:
body mass index; ABSI: a body shape index.
Table 3: Correlations in NHANES III.
hH hBMI hABSI hHI ARI Waist BP TG HDL Glu MS score MS
hH 1 −0.015 −0.012 −0.009 −0.015 0.074 0.030 −0.051 −0.014 −0.027 0.008 0.006
hBMI 1 0.032 0.080 0.775 0.388 0.116 0.104 0.123 0.100 0.284 0.215
hABSI 1 0.050 0.613 0.258 0.025 0.120 0.112 0.047 0.193 0.148
hHI 1 0.321 0.122 0.075 0.077 0.063 0.110 0.147 0.128
ARI 1 0.464 0.117 0.164 0.170 0.127 0.355 0.274
Waist 1 0.242 0.231 0.230 0.193 0.652 0.514
BP 1 0.202 0.033 0.231 0.584 0.438
TG 1 0.325 0.204 0.655 0.597
HDL 1 0.120 0.584 0.482
Glu 1 0.520 0.461
MS score 1 0.828
MS 1
Correlation coefficients among NHANES III nonpregnant adults. hH, hBMI, hABSI, and hHI refer to hazard ratio logarithms based on functional re-
lationships between mortality and the Z scores of the respective anthropometric measures height, body mass index, a body shape index, and hip index. ARI is
the sum of these 4 quantities. +e metabolic syndrome score MS score is the sum of scores for the waist circumference, blood pressure, triglyceride, high-
density lipoprotein, and glucose components defined in Table 1. Metabolic syndrome MS is defined as a score of 3 or more.
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ARI correlates better with the MS components than any one
ARI component does. ARI has a correlation of 0.36 with MS
score and 0.27 with MS (Table 3). Anthropometric mortality
risk is thus associated with MS, but not as closely associated
with MS as any of the MS definition components are.
+e fitted coefficients and performance indicators of the
proportional hazard models for mortality prediction are
given in Table 4. +e presence of MS increased mortality
hazard by 37% (95% confidence interval: 22–54%, model MS
in Table 4). MS score was a better population predictor than
MS occurrence, with eachMS component present increasing
mortality hazard by 15% (10–20%, model MS score). Sep-
arating the individual MS components suggests that Waist
and TG are not significantly associated with mortality, while
BP, HDL, and Glu are significantly and about equally as-
sociated with mortality (model MS components).
+e predictive model with ARI (model ARI) significantly
outperformed the models with only MS occurrence, MS
score, or MS components. However, a model with both ARI
and MS performed even better, with both ARI and MS
remaining as significant predictors (model ARI +MS). ARI
could also be combined with MS components, whereupon
BP, HDL, and Glu remained significant mortality predictors
(model ARI +MS components). In that case, the Waist
component of MS was just as well omitted (models ARI
+MSx score and ARI +MSx components), both because ARI
already has WC as an input and because Waist’s association
with mortality risk in this cohort was not significant.
Overall, among the models considered here, ARI+MSx
components, ARI+MS components, and ARI+MSx score
were statistically tied for best predicting mortality hazard as
measured by Δi. While the MS score significantly out-
performed MS occurrence as a mortality predictor, there was
not a firm basis for giving different weights to the MS com-
ponents to improve mortality prediction, as the performances
of MS components and MS score and ARI+MSx components
and ARI+MSx score, respectively, were statistically tied
(Table 4).
4. Discussion
Here, we for the first time evaluated, for mortality prediction
in the general population, the combination of a systemati-
cally selected set of independent anthropometrics (H, BMI,
ABSI, and HI, whose respective attributable hazards were
summed to give ARI) with MS. We found that although ARI
was the best single mortality predictor and was positively
correlated with all MS components, the clinical and labo-
ratory data that contribute to the MS score could be used
synergistically with ARI to further improve mortality pre-
diction. Such individualized risk information could poten-
tially be useful in a variety of clinical contexts for guiding
personalized medical care [44–46].
+ere are some limitations to our study. Our cohort was
relatively small in size, limiting statistical power, because
many of the NHANES III sample did not have the fasting
glucose and triglyceride measurements needed to evaluate
MS. +e long follow-up for mortality of approximately 20
years is a strength, but it is possible that associations of
anthropometrics and MS components with mortality hazard
have changed over time so that these findings would not be
fully applicable to current patients. Possible time changes in
associations with mortality have been most fully studied for
BMI, with inconclusive results so far [47, 48]. As well, the ATP
III definition of MS we used is one that has been employed in
previous analyses of NHANES III [38, 39, 49], but many
definitions have been proposed, with no single consensus
[1, 50]. While most patients retain their MS classification
across definitions [51], in some cases morbidity and mortality
associations were affected by the definition used [13, 52].
We found that hypertension, hyperglycemia, and low
HDL are the main drivers of the association of MS with
mortality hazard in NHANES III. Some studies have found
hyperglycemia to be the component of MS most associated
with mortality [2, 13]. +e strength of the mortality asso-
ciation with MS found in NHANES III is comparable to that
seen in other cohorts [11].
Table 4: Mortality hazard association with body measures and
metabolic syndrome in NHANES III.
Model Δi R2 C Predictor HR
Base 97.3 0.0148 0.543
ARI 27.1 0.0426 0.600 ARI 2.93 (2.30–3.73)
MS 71.2 0.0257 0.563 MS 1.37 (1.22–1.54)
MS score 55.1 0.0318 0.582 MS score 1.15 (1.10–1.20)
ARI+MS 19.1 0.0464 0.604 ARI 2.65 (2.06–3.40)
MS 1.22 (1.08–1.37)
ARI+MS
score 10.2 0.0498 0.610 ARI 2.52 (1.95–3.25)
MS score 1.10 (1.05–1.15)
ARI+MSx
score 5.5 0.0516 0.610 ARI 2.62 (2.05–3.36)
MSx score 1.13 (1.08–1.19)
MS
components 49.9 0.0369 0.598 Waist 1.12 (0.99–1.27)
BP 1.27 (1.10–1.45)
TG 0.94 (0.82–1.07)
HDL 1.23 (1.08–1.40)
Glu 1.31 (1.15–1.49)
ARI+MS
components 1.3 0.0562 0.617 ARI 2.68 (2.07–3.49)
Waist 0.95 (0.83–1.08)
BP 1.26 (1.10–1.44)
TG 0.93 (0.81–1.06)
HDL 1.23 (1.08–1.40)
Glu 1.25 (1.09–1.43)
ARI+MSx
components 0 0.0560 0.620 ARI 2.59 (2.02–3.33)
BP 1.25 (1.09–1.44)
TG 0.92 (0.81–1.05)
HDL 1.22 (1.07–1.38)
Glu 1.24 (1.09–1.42)
Results of Cox proportional hazardmodeling for mortality risk in NHANES
III with the linear predictors shown. All models also included as predictors
sex and race. +e hazard ratios are given with 95% confidence intervals.Δi �Akaike information criterion score difference relative to the best-
performing model shown (see Methods for details); R2 �measure of
explained variation; C� concordance; HR� hazard ratio.
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It would be interesting to compare the risk associations
seen with ARI and MS in the NHANES III national USA
sample with those from other countries. WC and BMI cutoffs
for cardiometabolic risks may vary between ethnicities
[53, 54], although ABSI, for example, has been found to have
comparable associations as a mortality predictor across co-
horts from several continents [21–25, 55, 56]. ARI and MS
could also be considered for prediction of morbidity such as
cardiovascular disease and diabetes, for which the relative
power of MS would be expected to be greater [11, 12].
Given the weak performance of a WC cutoff for de-
termining mortality risk, replacing the Waist component in
the definition of MS by a more sensitive anthropometric
indicator of abdominal obesity could be worth exploring.
Possible candidates are theWC/H ratio [15, 57–59], which is
linked to body roundness in an elliptical model of the human
body [60] and ARI itself (at least the sum of the BMI and
ABSI risks, which show the largest correlations with WC).
Similarly, given the lack of association of high TG with
mortality, one could also consider elimination of the TG
component in the definition of MS in favor of other mea-
sures such as elevated low-density lipoprotein cholesterol
[61] or TG/HDL ratio [62]. Larger cohorts and a fuller range
of health outcomes would probably be necessary to de-
finitively show the merits of these proposals.
5. Conclusions
In summary, we found that anthropometric parameters and
factors included in the definition of metabolic syndrome,
while not uncorrelated, can function synergistically as
predictors of mortality hazard, potentially improving in-
dividualized risk assessment compared to using either set of
predictors in isolation.
Data Availability
+e NHANES III data used to support the findings of this
study are publicly available online from the United States
National Center for Health Statistics
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